{"id":746480,"date":"2023-04-11T07:06:18","date_gmt":"2023-04-11T11:06:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/"},"modified":"2023-04-11T07:06:18","modified_gmt":"2023-04-11T11:06:18","slug":"athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/","title":{"rendered":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting"},"content":{"rendered":"
\n

\n Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer\u2019s disease patients including improvements in measures of cognition and plasma biomarkers<\/em>
\n \n <\/p>\n

\n Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF\/MET pathway with fosgonimeton in neurodegenerative conditions <\/em>\n <\/p>\n

\n Poster presentation to highlight beneficial effects of ATH-1105 on motor function and survival in an ALS animal model<\/em>\n <\/p>\n

BOTHELL, Wash., April 11, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, which will be held April 22-27, 2023, virtually and at the Boston Convention and Exhibition Center in Boston, Mass. The presentations will highlight additional clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton in people with mild-to-moderate Alzheimer\u2019s disease; preclinical data supporting fosgonimeton\u2019s mechanism of action and therapeutic potential for neurodegenerative diseases; and preclinical data for ATH-1105 for amyotrophic lateral sclerosis.<\/p>\n

\n AAN 2023 Presentation Details:<\/strong>\n <\/p>\n

\n Title: <\/strong>
\n Therapeutic Potential of Fosgonimeton, a Small-Molecule Positive Modulator of the Neurotrophic HGF\/MET Pathway, in Neurodegenerative Conditions<\/a>
\n
\n Format:<\/strong> Oral (abstract #3944, presentation #008)
Session:<\/strong> S14: General Neurology: Emerging Therapies
Presenter: <\/strong>Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma
Date\/Time:<\/strong> Monday, April 24, at 2:24 p.m. EDT<\/p>\n

\n Title: <\/strong>
\n Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer’s Disease<\/a>
\n
\n Format:<\/strong> Oral (abstract #4214, presentation #008)
Session:<\/strong> S26: Experimental Therapeutics in Dementia
Presenter: <\/strong>Hans J. Moebius, M.D., Ph.D., Chief Medical Officer, Athira Pharma
Date\/Time:<\/strong> Tuesday, April 25, at 2:24 p.m. EDT<\/p>\n

\n Title: <\/strong>
\n Small Molecule Positive Modulator of Hepatocyte Growth Factor (HGF)\/MET, ATH-1105, Improves Function and Reduces Disease Biomarkers in a TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis<\/a>
\n
\n Format:<\/strong> Poster (abstract #3277)
Session:<\/strong> P8: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1
Presenter: <\/strong>Jewel Johnston, Ph.D., Director, In Vivo Pharmacology, Athira Pharma
Date\/Date: <\/strong>Tuesday, April 25, from 11:45 a.m. – 12:45 p.m. EDT<\/p>\n

All presentations will be available on the Scientific Publications & Presentations<\/u><\/a> page of the company\u2019s website at www.athira.com<\/a>.<\/p>\n

\n About Athira Pharma, Inc.<\/strong>
\n
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF\/MET neurotrophic system for Alzheimer\u2019s and Parkinson\u2019s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit\u00a0www.athira.com<\/a>. You can also follow Athira on\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>, <\/u>and @athirapharma on Twitter<\/a> and\u00a0Instagram<\/a>.\u00a0<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This communication contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer\u2019s disease, Parkinson\u2019s disease dementia, Dementia with Lewy bodies, and other neurodegenerative diseases, such as amyotrophic lateral sclerosis; Athira\u2019s platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; expectations regarding the potential efficacy and commercial potential of Athira\u2019s product candidates; and Athira\u2019s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201con track,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cpursue,\u201d \u201ccontinue,\u201d \u201csuggest,\u201d \u201cpotential,\u201d and other similar expressions, among others. Any forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data for our product candidates from our preclinical and clinical trials not supporting the safety, efficacy and tolerability of our product candidates; cessation or delay of Athira\u2019s development of product candidates may occur; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira\u2019s business, research and clinical development plans and timelines, and the regulatory process for Athira product candidates; Athira may not be able to recruit sufficient patients for its clinical trials;\u00a0the outcome of legal proceedings that have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira\u2019s product candidates; possible negative interactions of Athira’s product candidates with other treatments;\u00a0Athira\u2019s assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira\u2019s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira\u2019s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.<\/p>\n

\n Investor & Media Contact<\/strong>
\n
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com<\/a>
206-769-9219<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer\u2019s disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF\/MET pathway with fosgonimeton in neurodegenerative conditions Poster presentation to highlight beneficial effects of ATH-1105 on motor function and survival in an ALS animal model BOTHELL, Wash., April 11, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, which will be held April 22-27, … <\/p>\n

Continue reading “Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746480","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAthira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer\u2019s disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF\/MET pathway with fosgonimeton in neurodegenerative conditions Poster presentation to highlight beneficial effects of ATH-1105 on motor function and survival in an ALS animal model BOTHELL, Wash., April 11, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, which will be held April 22-27, … Continue reading "Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T11:06:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting\",\"datePublished\":\"2023-04-11T11:06:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/\"},\"wordCount\":1010,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/\",\"name\":\"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=\",\"datePublished\":\"2023-04-11T11:06:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk","og_description":"Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer\u2019s disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF\/MET pathway with fosgonimeton in neurodegenerative conditions Poster presentation to highlight beneficial effects of ATH-1105 on motor function and survival in an ALS animal model BOTHELL, Wash., April 11, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, which will be held April 22-27, … Continue reading \"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-11T11:06:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting","datePublished":"2023-04-11T11:06:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/"},"wordCount":1010,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/","name":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=","datePublished":"2023-04-11T11:06:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTI3MCM1NTE5MzMzIzIyMDE4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-upcoming-presentations-at-the-american-academy-of-neurology-aan-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746480"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746480\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}